

Buprenorphine Outpatient OB Order Set: Standard Induction Quick Start

CLINICAL PEARLS

Buprenorphine should not be given to patients who are currently taking **methadone**, as this would **cause withdrawal**. Please coordinate with patient's methadone clinic provider if patient has been receiving methadone treatment and desires to change to buprenorphine.

Methadone may be a good option for patients who are struggling to initiate buprenorphine, have been unsuccessful with buprenorphine treatment in the past, or prefer methadone due to not having to experience opioid withdrawal prior to initiation.

Both methadone and buprenorphine are **recommended** medications for treatment of **opioid use disorder in pregnancy**, and one is not better than the other.

Most patients can be safely initiated on buprenorphine in the home setting, unless there are cognitive needs or medical concerns for the safety of the mother and/or baby.

Observation admission and fetal monitoring are not required in an average risk pregnancy.

Buprenorphine & naloxone **combination product** (and methadone) is **safe** for use in pregnancy and breastfeeding.

No Prior Authorization Required for Suboxone Brand SL films.

Prior Auth required for buprenorphine **mono product**, as well as any buprenorphine doses **>24 mg/day**

Colorado Medicaid PA Phone Number: 1-800-424-5725 Need patient full name, DOB, Medicaid ID #

MEDICATIONS FOR OPIOID USE DISORDER

✓ Buprenorphine-Naloxone 8mg-2mg Sublingual Film
 May substitute buprenorphine 8 mg SL Tablet, if patient cannot take film
 Quantity: Sufficient to last until follow up appointment date and time

Initiate 4 mg (one half film) SL once, in clinical setting or at home once withdrawal has started.

Start Time:

Fentanyl Use: Initiate once SOWS >13 and 24-36 hours has elapsed since last reported or suspected use of fentanyl

Short-Acting Opioid Use (heroin, oxycodone, tramadol, kratom, etc): Initiate once SOWS > 13 and 12-18 hours has elapsed since last reported or suspected use of a short acting opioid

Methadone Use: Initiate once SOWS >13 and 36 hours has elapsed since last reported or suspected use of methadone

If withdrawal has improved 1 hour after dose, continue with dosing at 4 mg (one half film) SLTID (12 mg daily)

If symptoms return, may increase dosing as shown below

If still symptomatic:

Patient may take additional 4 mg (one half film) dose

If withdrawal has improved 1 hour after taking second 4 mg dose (8 mg total), continue with dosing at 8 mg (1 film) SL BID (16 mg daily)

If symptoms return, may increase dosing as shown below

If still symptomatic:

Patient may take additional 8 mg (1 film) dose

If withdrawal has improved 1 hour after taking 8 mg dose (16 mg total), continue with dosing at 16 mg (2 films) SL BID (32 mg daily)

If withdrawal has **NOT** improved or has **worsened**, **may consult** addiction specialist

NALOXONE

| ☑ Naloxone 4 mg Nasal Spray, Quantity: 2 |
|---|
| Administer 4 mg nasally as needed for opioid overdose |
| Provide as a Take Home Kit, if possible. Otherwise, send prescription to pharmacy |
| ADJUNCT TREATMENTS (+/-) |
| ☐ Clonidine 0.1 mg orally q4h PRN restlessness, hot/cold flashes or anxiety |
| ☐ Hydroxyzine 25-50 mg orally q6h PRN anxiety or insomnia |
| ☐ Ondansetron 4 mg orally q6h PRN nausea |
| ☐ Dicyclomine 10 mg orally TID PRN abdominal cramping |
| ☐ Trazodone 50-100 mg orally qHS PRN insomnia |
| ☐ Acetaminophen 500-1000 mg orally q6h PRN headache, pain |
| ☐ Gabapentin 300 mg orally TID PRN restless legs, anxiety, agitation |
| ☐ Promethazine 12.5-25 mg orally q6h PRN nausea (if preferred to ondansetron, or not having success with ondansetron) |
| LABORATORY (IN ADDITION TO STANDARD OB LABORATORY ORDERS) |
| □ HIV |
| ☐ Hepatitis B Antigen and Antibody |
| ☐ Hepatitis C Antibody with reflex RNA |
| ☐ RPR/Treponema |
| ☐ Urine screen for Chlamydia/Gonorrhea, Trichomonas |
| ☐ CBC and CMP |
| INFECTIOUS DISEASE CONSIDERATIONS |
| ☐ Treat/ refer for treatment of sexually transmitted infections |
| ☐ Offer PrEP for patients with injection use, partners with injection use and/or |
| transactional sex/ sex work |
| REFERRALS |
| ☐ Harm Reduction Services |
| ✓ Peer Support Services |
| ✓ Outpatient Behavioral Health Services |
| ☐ Outpatient Prenatal Care/ Postpartum Care |
| ☐ Outpatient Pediatric/ Family Medicine |
| FOLLOW UP APPOINTMENT |

This resource has been developed by the MOMs+ interdisciplinary team based on published evidence and expert opinion. This material should not be reproduced or disseminated without prior permission from MOMs+ or Stader Opioid Consultants, LLC. This resource should never be used as a substitute for clinical judgment. Providers are responsible for assessing the unique circumstances and needs of each case. Adherence to this guideline will not ensure successful treatment in every situation. Developed in collaboration with Stader Opioid Consultants, LLC.

☑ Outpatient SUD Provider in 5-7 days, or sooner if appointment available (in person or telemedicine)